First Time Loading...
N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 27.82 CNY 0.54%
Updated: Apr 30, 2024
Section:
 

Relative Value

The Relative Value of one Nanjing Vazyme Biotech Co Ltd stock under the Base Case scenario is 31.06 CNY. Compared to the current market price of 27.82 CNY, Nanjing Vazyme Biotech Co Ltd is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
31.06 CNY
Undervaluation 10%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
70
vs Industry
64
Median 3Y
6.3
Median 5Y
6.3
Industry
8.1
Forward
8.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
8
Median 3Y
31.9
Median 5Y
31.9
Industry
26.2
Forward
-636
More Details
18.9
P/OCF
P/OCF
Price to OCF
18.9
vs History
80
vs Industry
9
Median 3Y
29.4
Median 5Y
29.4
Industry
22.6
More Details
10
P/FCFE
P/FCFE
Price to FCFE
10
vs History
41
vs Industry
9
Median 3Y
8.8
Median 5Y
8.8
Industry
21.3
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
83
vs Industry
34
Median 3Y
4.6
Median 5Y
4.6
Industry
2.5
More Details
4.2
EV/S
EV/S
Enterprise Value to Sales
4.2
vs History
77
vs Industry
57
Median 3Y
5.3
Median 5Y
5.3
Industry
7.3
Forward
7.1
More Details
6.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.4
vs History
74
vs Industry
50
Median 3Y
8.8
Median 5Y
8.8
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
10
Median 3Y
25
Median 5Y
25
Industry
4.4
Forward
58.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
9
Median 3Y
25
Median 5Y
25
Industry
4.3
Forward
-152.3
More Details
15.1
EV/OCF
EV/OCF
Enterprise Value to OCF
15.1
vs History
80
vs Industry
10
Median 3Y
25.1
Median 5Y
25.1
Industry
5.4
More Details
58.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
58.6
vs History
35
vs Industry
3
Median 3Y
0
Median 5Y
0
Industry
3.2
More Details
4.3
EV/IC
EV/IC
Enterprise Value to IC
4.3
vs History
83
vs Industry
35
Median 3Y
7.5
Median 5Y
7.5
Industry
5
More Details

Multiples Across Competitors

Competitors Multiples
Nanjing Vazyme Biotech Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Nanjing Vazyme Biotech Co Ltd
SSE:688105
11.1B CNY 5.2 -48 -28.1 -28.1
US
Abbvie Inc
NYSE:ABBV
285.2B USD 5.3 59.2 12.9 19.6
US
Amgen Inc
NASDAQ:AMGN
148B USD 5.2 22 16.4 24.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.1B USD 10.3 28.2 22.5 23.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.6B USD 7.4 24.7 16.3 17.9
AU
CSL Ltd
ASX:CSL
132.9B AUD 6.2 35.3 21.4 26.5
US
Gilead Sciences Inc
NASDAQ:GILD
82.2B USD 3 14.5 8 10.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
42.6B USD 6.2 -9 -9.6 -8.2
US
Biogen Inc
NASDAQ:BIIB
31.2B USD 3.2 26.9 14.5 18
KR
Celltrion Inc
KRX:068270
39.3T KRW 18.1 73.5 45 61.9
EV/EBITDA Multiple
EBITDA Growth
CN
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Average EV/EBITDA: 19.6
Negative Multiple: -28.1
-34%
US
Abbvie Inc
NYSE:ABBV
12.9
26%
US
Amgen Inc
NASDAQ:AMGN
16.4
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
50%
AU
CSL Ltd
ASX:CSL
21.4
54%
US
Gilead Sciences Inc
NASDAQ:GILD
8
18%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9.6 N/A
US
Biogen Inc
NASDAQ:BIIB
14.5
67%
KR
Celltrion Inc
KRX:068270
45
109%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.